SciSparc's Phase IIb clinical trials for SCI-110, a potential therapy for Tourette Syndrome, have been approved by the FDA. The trial will be conducted at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center, focusing on efficacy, safety, and tolerability of the drug in adult patients.